Company Overview of Foresight Biotherapeutics, Inc.
Foresight Biotherapeutics, Inc., a clinical-stage drug development company, develops treatments/therapies to address unmet needs in ophthalmology and otolaryngology. The company focuses on the diseases of eye and ear. Its product candidates include FST-100 for the clinical needs of microbial eradication and reduction in inflammation associated with ocular infections, as well as for adenoviral conjunctivitis; and FST-201, a topical formulation of povidone-iodine and dexamethasone for the treatment of acute otitis media. The company was incorporated in 2008 and is based in New York, New York. As of July 30, 2015, Foresight Biotherapeutics, Inc. operates as a subsidiary of Shire plc.
50 West 57th Street
New York, NY 10019
Founded in 2008
Key Executives for Foresight Biotherapeutics, Inc.
Similar Private Companies By Industry
|Colloral LLC||United States|
|Positron Pharmaceuticals Company||United States|
|Aventis Inc.||United States|
|Eurand Pharmaceuticals Inc.||United States|
|Acelerox, LLC||United States|
Recent Private Companies Transactions
August 3, 2015
To contact Foresight Biotherapeutics, Inc., please visit www.foresightbio.com. Company data is provided by Capital IQ. Please use this form to report any data issues.